论文部分内容阅读
目的分析以LUNX-mRNA为标志物,RT-PCR法检测非小细胞肺癌(NSCLC)纵隔淋巴结微转移的可行性,从基因水平探讨肺癌系统性纵隔淋巴结清扫的必要性。方法对20例NSCLC 患者术中取纵隔淋巴结,用RT-PCR法检测肺癌特异性基因LUNX在纵隔淋巴结的表达情况,并与10 例肺部良性疾病患者的纵隔淋巴结LUNX基因的表达进行对比。结果20例肺癌患者共送检71枚纵隔淋巴结。常规病理学检查阳性的淋巴结占11．3％;而LUNX-mRNA阳性的淋巴结占32．4％,P< 0．001;纵隔淋巴结微转移率为25．4％;在ⅠA-ⅡB期患者的55枚纵隔淋巴结中,LUNX-mRNA阳性的淋巴结占23．6％,而在Ⅲ期患者的16枚淋巴结中,LUNX-mRNA阳性的淋巴结占62．5％(P= 0．003)。结论可手术NSCLC患者的纵隔淋巴结微转移发生率约为25．4％;系统性胸内淋巴结清扫应为NSCLC患者的标准术式之一。
Objective To analyze the feasibility of using LUNX-mRNA as a marker and detecting the micrometastases of mediastinal lymph nodes in non-small cell lung cancer (NSCLC) by RT-PCR and to explore the necessity of systematic mediastinal lymph node dissection in lung cancer from the gene level. Methods The mediastinal lymph nodes were obtained from 20 NSCLC patients. The expression of LUNX gene in mediastinal lymph nodes was detected by RT-PCR and compared with that of LUNX gene in 10 patients with benign lung diseases. Results A total of 71 mediastinal lymph nodes were obtained from 20 patients with lung cancer. Routine pathological examination of lymph nodes accounted for 11.3%; while LUNX-mRNA positive lymph nodes accounted for 32.4%, P <0.001; mediastinal lymph node micrometastasis rate was 25.4%; in patients with stage IA-IIB In 55 mediastinal lymph nodes, LUNX-mRNA positive lymph nodes accounted for 23.6%, while LUNX-mRNA positive lymph nodes accounted for 62.5% of the 16 lymph nodes in stage III patients (P = 0.003). Conclusions The incidence of mediastinal lymph node micrometastases in patients with operable NSCLC is about 25.4%. Systematic dissection of the intrathoracic lymph nodes should be one of the standard procedures for patients with NSCLC.